PARP1 and ovarian carcinoma: Certain PARP inhibitors (PARPi) are FDA-approved to treat breast, prostate, and gynecologic cancers including ovarian cancer (21–23), and there are numerous clinical trials underway to extend their use to other malignancies (Table 1).